Studies continue to demonstrate the clinical benefits of the multi-technology platform Сaris Molecular Intelligence (CMI), as well as the clinical benefit of composing a molecular “fingerprint” tumor for cancer diagnosis. Clinical benefit is in assisting the physician to choose clinically effective treatments, as well as the positive effect on the overall survival patients with cancer.
Two studies, one in a large group of patients with “refractory”, metastatic or rare cancer in 2015, and the second in the group of patients with ovarian cancer in 2014, showed that patients who were treated according to the recommendations of the clinical platform diagnosis of Caris CMI, showed greater survival and less medication (minimizing potential toxicity and additional cost of treatment) than patients who did not receive CMI recommendations.
